Plasmid DNA Residual Detection Kit

Plasmid DNA is a core raw material and critical vector for gene therapy, mRNA vaccines, and cell therapy products. From FDA guidelines to the 2025 edition of the Chinese Pharmacopoeia, global regulatory systems have established stringent control standards for residual DNA in biological products. Residual plasmid DNA not only carries risk elements such as antibiotic resistance genes and prokaryotic CpG immunostimulatory sequences, but its physicochemical properties are also close to those of viral particles and mRNA products, making purification and removal highly challenging. It has thus become a critical hurdle that must be overcome in the CMC quality control system. Yeasen Biotechnology's independently developed Plasmid DNA Residual Detection Kit (41323ES), relying on qPCR probe technology, provides an ultra-high sensitivity of 4 copies/μL, a fully validated compliance system, and comprehensive supporting services, building a solid quality control defense line for plasmid residuals in gene therapy, mRNA vaccines, and cell therapy products.

1. Industry Background: The Boom in CGT and mRNA Amplifies Residual Quality Control Demands

Cell and gene therapy (CGT), mRNA vaccines, and drugs are entering a fast lane of industrialization. Plasmid DNA serves both as a template for in vitro transcription (IVT) of mRNA and as a core starting material for the transient transfection of viral vectors such as AAV and lentivirus.

According to joint statistics from ASGCT and Citeline, as of the third quarter of 2025, there were 3,243 ongoing gene, cell, and RNA therapy clinical trials globally. Driven by this, the market scale of plasmid DNA as an upstream core raw material is rapidly expanding. According to Grand View Research, the global plasmid DNA manufacturing market size was approximately $2.43 billion in 2025, and is expected to reach about $9.29 billion by 2033, with a compound annual growth rate (CAGR) of approximately 18.5%. With capacity expansion, the demand for plasmid residual quality control is amplifying synchronously—high-sensitivity, fully-verifiable residual DNA testing is shifting from an 'optional choice' to a 'mandatory requirement' in the CMC system.

2. Safety Risks and Global Regulatory Framework of Residual Plasmid DNA

2.1 Main Risks of Residual Plasmid DNA

While playing a crucial role, plasmid DNA also brings safety hazards that cannot be ignored. During the production and purification of biological products, even after multi-step chromatography and nuclease treatment, trace amounts of plasmid DNA may still remain in the final product. These residuals primarily pose the following potential risks:
Immunogenicity Risk: Residual plasmid DNA may be recognized as a 'foreign substance' by the human immune system, triggering inflammatory responses, allergies, or even autoimmune diseases. Unmethylated CpG sequences of prokaryotic origin in plasmid DNA can activate innate immune pathways such as TLR9, leading to adverse reactions like fever and local inflammation.
Gene Integration Risk: If residual DNA fragments carry complete antibiotic resistance genes or functional expression elements, there is a theoretical potential risk of insertion into the host cell genome and abnormal activation of proto-oncogenes.
Infectious Risk: If plasmid DNA carries virus-derived regulatory sequences (such as the SV40 promoter), it may introduce potential biological hazards.

2.2 Global Mainstream Regulatory Standards

Drug regulatory agencies worldwide have established strict limit standards for DNA residuals in biological products, and requirements are becoming increasingly stringent with technological developments:

Table 1. Summary of mainstream global regulatory standards

2.3 Consensus on Detection Methodology

Due to its high sensitivity and high specificity, quantitative PCR (qPCR) has become the mainstream detection method in the industry. qPCR detection kits equipped with fully validated data have become core tools for the release of biological products—Yeasen 41323ES was precisely designed and developed based on this demand.

3. Detailed Product Overview of Plasmid DNA Residual Detection Kit (Cat#41323ES) 

Yeasen Biotechnology's independently developed Plasmid DNA Residual Detection Kit (Cat#: 41323ES) is a dedicated kit used for the quantitative analysis of residual plasmid DNA in biological products such as vaccines, gene and cell therapy products. This kit designs specific primers targeting the common DNA sequences of plasmids used in the market, adopts the qPCR fluorescent probe principle, and specifically and rapidly detects residual plasmid DNA. The kit is supplied with a linear Plasmid DNA Control (plasmid DNA quantification reference). It can be used in conjunction with Yeasen's Magnetic Bead-based Residual DNA Sample Pretreatment Kit (Cat#18469ES) to achieve full-process coverage from sample pretreatment to detection.

3.1 Application Scenarios

Cell and Gene Therapy Products: Covers the residual plasmid detection needs from R&D to product release, paying special attention to the risk nodes of co-elution of plasmids and viral particles in the late purification stage of AAV and lentiviral vectors, providing data support for the safety release of final products.
mRNA Vaccines and Therapeutic Drugs: Accurately detects linear plasmid template residuals in the IVT bulk solution. Residuals at this step directly enter the finished product without a secondary removal opportunity, making it a core indicator for the release of mRNA drugs.
Recombinant Protein and Antibody Drugs: Targeting engineered cell line expression systems constructed using plasmids, used during process verification to confirm the clearance efficiency of plasmid backbone sequences.

3.2 Product Features

Anti-Interference: For complex matrices, the sample spike recovery rate can reach at least 70~130%;
High Sensitivity: The Lower Limit of Quantification (LLOQ) is 4 copies/μL;
High Precision: Small inter-batch differences, intermediate precision CV < 15%;
Strong Specificity: Specifically detects residual plasmid DNA without interference from other exogenous genomic DNAs;
Strong Anti-Interference Feature: Introduces an Internal Control (IC) to eliminate factors such as sample interference and reaction preparation abnormalities, effectively avoiding false negatives;
Comprehensive Validation: Referenced to ICH Q2 (R2) analytical method validation guidelines, capable of providing complete validation reports;
Regulatory Compliance: Validated according to EP 2.6.7, JP 3, and USP 63 pharmacopoeia requirements, conforming to standards of international authoritative institutions;
Quality Assurance: All enzyme raw materials required for the kit are self-produced and industrialized, ensuring stable supply.

3.3 Summary of Complete Methodological Validation Parameters

Table 2. Summary of Methodological Validation Parameters

 

1) Standard Curve Linearity

The linear range of the kit is: 4 × 10¹ copies/μL ~ 4 × 10⁶ copies/μL, R² = 1, 90% ≤ amplification efficiency ≤ 110%, and the detected values at each concentration have a CV < 15%.

 Figure 1. Linear standard curve plot of plasmid DNA (left) and linear amplification curve profile (right)

2) Quantitation Limit

Blank sample spike recovery experiment:
Plasmid DNA samples at three concentrations (4 × 10⁵ copies/µL, 4 × 10³ copies/µL, and 4 × 10¹ copies/µL) were tested in 3 replicates to analyze sample recovery and CV. The recovery rates for DNA samples at different concentrations were all between 70% and 130%, and CVs were all < 20%.

Table 3. Spike recovery rate of blank samples

 

3) Accuracy

Plasmid DNA at concentrations of 10 copies/µL, 4 copies/µL, and 1 copy/µL was tested with 10 replicates per concentration. The results show that at concentrations of 4 copies/µL and above, the CV is < 20%, indicating that the quantitation limit of the Plasmid DNA Residual Detection Kit can reach 4 copies/µL.

 Figure 2. qPCR detection results of 4 copies/μL plasmid DNA

Table 4. Limit of quantitation (LOQ) detection results for plasmid DNA

Replicate	Quantity (copies/μL)	Recovery Rate
1	5.33	133.15%
2	4.14	103.45%
3	5.54	138.44%
4	4.47	111.77%
5	5.85	146.27%
6	4.94	123.59%
7	3.63	90.85%
8	4.3	107.49%
9	4.1	102.39%
10	4.37	109.19%
Mean	4.67	-
CV	15.33%	-

4. Conclusion

Against the backdrop of tightening regulatory inspections and the normalization of dual-filing in China and the US, plasmid DNA residual testing has become a quality defense line that gene therapy, mRNA vaccine, cell therapy, and recombinant protein companies must secure. The official implementation of the 2025 edition of the Chinese Pharmacopoeia has further raised the testing standards for exogenous DNA residuals in biological products. Yeasen 41323ES Plasmid DNA Residual Detection Kit, with its ultra-high sensitivity of 4 copies/μL, supply chain guarantees from self-produced enzymes, and a validation system fully compliant with domestic and international regulations, provides full-chain quality control support from process development to commercial release for biological products such as gene therapy, mRNA vaccines, and recombinant proteins, escorting the safe launch of every innovative biopharmaceutical.

5. Related Products

Product Name	Item	Size
MolPure™ Magnetic Sample Preparation Kit (Bottled, Fast Version)	18469ES	25T/100T
Plasmid DNA Residue Detection Kit	41323ES	50T/100T